- Q1 2024 Relmada Therapeutics Inc Earnings Call TranscriptMay 08, 2024€3.54Earnings
- Q4 2023 Relmada Therapeutics Inc Earnings Call TranscriptMar 19, 2024€4.98 (-1.39%)Earnings
- Q3 2023 Relmada Therapeutics Inc Earnings Call TranscriptNov 08, 2023€2.78 (-4.79%)Earnings
- Q2 2023 Relmada Therapeutics Inc Earnings Call TranscriptAug 08, 2023€2.36 (+4.42%)Earnings
- Relmada Therapeutics Inc at Goldman Sachs Healthcare Conference TranscriptJun 14, 2023
- Relmada Therapeutics Inc at Jefferies Healthcare Conference TranscriptJun 08, 2023
- Q1 2023 Relmada Therapeutics Inc Earnings Call TranscriptMay 11, 2023€2.94 (-2.65%)Earnings
- Q4 2022 Relmada Therapeutics Inc Earnings Call TranscriptMar 23, 2023€2.16 (-5.26%)Earnings
- Relmada Therapeutics Inc Top-line Results from Phase 3 RELIANCE I Trial for REL-1017 as an Adjunctive Treatment for Major Depressive Disorder - Corporate Call TranscriptDec 07, 2022
- Q3 2022 Relmada Therapeutics Inc Earnings Call TranscriptNov 10, 2022€5.9Earnings
- Q2 2022 Relmada Therapeutics Inc Earnings Call TranscriptAug 11, 2022€28 (+6.06%)Earnings
- Relmada Therapeutics Inc at Goldman Sachs Global Healthcare Conference TranscriptJun 14, 2022
- Q1 2022 Relmada Therapeutics Inc Earnings Call TranscriptMay 05, 2022€22.6 (-3.42%)Earnings
- Q4 2021 Relmada Therapeutics Inc Earnings Call TranscriptMar 23, 2022€21.2 (+8.72%)Earnings
- Relmada Therapeutics Inc Results of Human Abuse Potential Study of REL-1017 vs. Ketamine - Corporate Call TranscriptFeb 23, 2022
- Q3 2021 Relmada Therapeutics Inc Earnings Call TranscriptNov 11, 2021€21.4Earnings
- Relmada Therapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 10, 2021
- Q2 2021 Relmada Therapeutics Inc Earnings Call TranscriptAug 10, 2021€19 (-3.55%)Earnings
- Relmada Therapeutics Inc REL-1017 Clinical Data Update Call TranscriptJul 27, 2021
- Q1 2021 Relmada Therapeutics Inc Earnings Call TranscriptMay 12, 2021€28.2Earnings
- Q4 2020 Relmada Therapeutics Inc Earnings Call TranscriptMar 23, 2021€29 (+0.17%)Earnings
Q2 2022 Relmada Therapeutics Inc Earnings Call Transcript
Good day, ladies and gentlemen, and welcome to the Relmada Therapeutics, Inc. Second Quarter 2022 Earnings Conference Call. Today's conference is being recorded. At this time, I would like to turn the conference over to Brian Ritchie of LifeSci Advisor. Please go ahead, sir.
Thank you, operator, and thank you all for joining us this afternoon. With me on today's call are Chief Executive Officer, Sergio Traversa; John Hixon, Head of Commercial; and Chief Financial Officer, Maged Shenouda. This afternoon, Relmada issued a news release providing a business update announcing financial results for the 3 and 6 months ended June 30, 2022, and filed its quarterly report on Form 10-Q with the SEC.
Please note that certain information discussed on the call today is covered under the safe harbor provision of the Private Securities Litigation Reform Act. We caution listeners that during this call, while Relmada's management team will be making forward-looking statements. Actual results could differ materially from those
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)